---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-007712"
form_type: "8-K"
ticker: "VSTM"
cik: "0001526119"
company_name: "Verastem, Inc."
filed_at: "2024-01-29T23:59:59+00:00"
generated_at: "2026-06-06T15:54:01.670652+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Verastem outlines 2024 priorities: NDA submission for avutometinib/defactinib in LGSOC in H1 2024

## Summary
- Plans to begin rolling NDA submission for accelerated approval of avutometinib/defactinib in recurrent LGSOC in H1 2024; potential commercial launch in 2025.
- Initial data from RAMP 205 trial of avutometinib/defactinib plus chemo in frontline metastatic pancreatic cancer expected H1 2024.
- Data from RAMP 203 and RAMP 204 trials in KRAS G12C-mutant NSCLC planned for mid-2024.
- Interim RAMP 201 results showed ORR 45% (13/29) and disease control 86% (25/29) in LGSOC; Phase 3 RAMP 301 initiated.
- Collaborator GenFleet to advance oral KRAS G12D inhibitor GFH375/VS-7375 into Phase 1 in 2024.

## SEC filing metadata
- accession: 0001104659-24-007712
- form_type: 8-K
- ticker: VSTM
- cik: 0001526119
- company_name: Verastem, Inc.
- filed_at: 2024-01-29T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1526119/000110465924007712/0001104659-24-007712-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1526119/000110465924007712/tm244111d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-007712
- JSON: https://secwatch.observer/filing/0001104659-24-007712.json
- Plain text: https://secwatch.observer/filing/0001104659-24-007712.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.